Privacy preference

MEDtalks would like to keep you informed about the content that is most relevant to you. Click here for more information.


Treatment of advanced melanoma

Over the last decade, the treatment of advanced melanoma has been significantly changed with the development of targeted therapy and immunotherapy. Now, we finally have five-year survival data for both kinds of treatments. How do these results impact daily clinical practice?

MEDtalks brings you an on demand e-learning (recorded on January 21st, 2020), in which a Belgian expert panel discusses first and second line treatment of advanced melanoma with targeted therapy and immunotherapy. Furthermore, the burning question on everybody’s mind after the presentation of the five-year survival results of the CheckMate 067 trial is of course not left untouched: should patients be treated with combination immunotherapy or monotherapy? And besides this systemic armamentarium, what is the role of local treatment options in the current treatment of (brain) metastasized melanoma?

Panel members

  • Prof. Bart Neyns, MD, PhD - medical oncologist, University Hospital of Brussels
  • Prof. Vibeke Kruse, MD, PhD - medical oncologist, Ghent University
  • Annemie Rutten, MD, PhD - medical oncologist, GZA Hospital Sint-Augustinus
  • Prof. Dirk van Gestel, MD, PhD - radiation oncologist, Institut Jules Bordet

Subjects (among others)

  • Five-year survival rate of targeted therapy and immunotherapy;  
  • First and second line systemic treatment of advanced melanoma;
  • Combination immunotherapy versus monotherapy anti-PD1 subsequently followed by anti-CTLA4;
  • Management of patients with poor prognostic factors (e.g. brain metastases) with both systemic and local therapy.

This e-learning is accredited for Dutch oncologists (1 CME point).
We are requesting accreditation for medical oncologists in Belgium. Points are credited as soon as accreditation has been granted.

  • Sponsors

    This program is editorially independent and is financially supported by:

Related items

Congress news 23/11/2019

SMR 2019: Peter Lau

Peter Lau has examined the efficacy of second line treatment of brain metastasis with the combination ipilimumab and nivolumab after progression on targeted therapy and will present this data.

Congress news 23/11/2019

SMR 2019: Mitchell Fane

Mitchell Fane talks about his research of changes in the microenvironment and the immune system that create a permissive niche for metastatic outgrowth of melanoma cells in the lung. These changes occur in the elderly patient. He will expand on what this means for further research.

Congress news 23/11/2019

SMR 2019: Eva Perez

Eva Perez-Guijarro, PhD, explains how preclinical mouse models in the National Cancer Institute are used to predict the response of immunotherapy and to identify new predictive biomarkers. Human clinical datasets are used to validate these potential biomarkers.

Congress news 23/11/2019

SMR 2019: Top 3 highlights

On the SMR 2019 an innumerable ammount of data, both clinical and preclinical, has been presented. Prof. Sean Morrison gives his personal highlights of this congress.

Congress news 23/11/2019

SMR 2019: Nethanel Asher

It is always interesting and insightful to see how results of clinical trials translate to daily clinical practice. Dr. Nethanel Asher runs you through the real world outcomes of the combination of ipilimumab and nivolumab in patients with advanced melanoma.

Congress news 23/11/2019

SMR 2019: Grant McArthur

It was already clear that the BRAF/MEK-combination cobimetinib + vemurafenib performs better then vemurafenib + placebo in terms of efficacy. On the SMR 2019 five-year survival results were presented. Prof. Grant McArthur talks you through the efficacy and toxicity and discusses the significance of these new data on daily clinical practice.

Congress news 23/11/2019

SMR 2019: Pier Ferrucci

There are a couple of ongoing trials examining the combination of immunotherapy and targeted therapy. One of them is the KEYNOTE-022 trial. Dr. Pier Francesco Ferrucci comments on the efficacy and toxicity of the combination of pembrolizumab, dabrafenib and trametinib in comparison to dabrafenib, trametinib and placebo.

Congress news 23/11/2019

SMR 2019: Rutao Cui

Up till now, there is no treatment that specifically targets the NRAS mutated melanoma, although MEK-inhibition shows some effect. Prof. Rutao Cui is developing a new therapeutic strategy, targeting up and downstream signaling pathways for NRAS mutated melanoma.